Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
In Vitro Diagnostics

PUBLISHER: MarketsandMarkets | PRODUCT CODE: 1462803

Cover Image

PUBLISHER: MarketsandMarkets | PRODUCT CODE: 1462803

Sepsis Diagnostics Market Size By Technology (Microbiology, PCR, Immunoassay, microfluidics, Biomarker), Product (Media, Reagent, Instrument), Method (Automated), Test (Lab, POC), Pathogen (Bacterial, Fungal), End User & Region - Global Forecast to 2029

PUBLISHED:
PAGES: 264 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 4950
PDF (5-user License)
USD 6650
PDF (Corporate License)
USD 8150
PDF (Global License)
USD 10000

Add to Cart

Description

Table of Contents

The global sepsis diagnostics market is projected to reach USD 890 million by 2029 from USD 634 million in 2024, growing at a CAGR of 7.0% during the forecast period. The increasing number of sepsis diagnostics procedures is one of the major factors anticipated to boost market growth in the forecasting years. Additionally, the high cost of diagnostic devices affects the growth of the sepsis diagnostics market.

Scope of the Report
Years Considered for the Study2021-2029
Base Year2023
Forecast Period2024-2029
Units ConsideredValue (USD) Million
SegmentsTechnology, Product, Method, Pathogen Type, Test Type, End user, and Region
Regions coveredNorth America, Europe, Asia Pacific, Latin America, and the Middle East & Africa

"The blood culture segment to hold the largest share of the market in 2024."

Based on technology, sepsis diagnostics is segmented into blood culture, immunoassays, molecular diagnostics, flow cytometry, microfluidics, and biomarkers. Blood culture segment is expected to dominate the sepsis diagnostics market during the forecast period. With the increasing sepsis incidences and this technique be the standard technique leading to the growth of this market segment.

"The blood culture media segment to hold the largest share of the market in 2024."

Based on product, the sepsis diagnostics market is segmented into mesh, sutures, mesh fixator, and other products. The sepsis diagnostics market is expected to be dominated by blood culture media segment during the forecast period. The blood culture media is expected to grow due to their affordable prices as compared to other sepsis diagnostics products.

"The bacterial sepsis segment to hold the largest share of the market in 2024."

Based on the pathogen type, the sepsis diagnostics market is segmented into bacterial sepsis, fungal sepsis, and other pathogens. The bacterial sepsis segment is further divided into gram-positive bacteria sepsis and gram-negative bacteria sepsis. The bacterial sepsis segment is estimated to hold the largest market share of the sepsis diagnostics market during the forecast period. Rising number of bacterial sepsis cases leads to the increasing growth of the segment in the market.

"The hospitals & speciality clinics segment to hold the largest share of the market in 2024."

The end user market is segmented into hospitals & speciality clinics, pathology & reference laboratories, and research laboratories, academic institutes & CROs . Hospitals & speciality clinics accounted for the largest share of the global sepsis diagnostics market in 2023 during the forecasted years. This can be attributed to the high patient inflow in this care setting. Only hospitals and clinics can provide the care and monitoring required in exceptionally severe cases, which also accounts for their dominance in the market.

"The market in the North America region is expected to hold a significant market share for sepsis diagnostics in 2022."

The sepsis diagnostics market covers five key geographies-North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. In 2023, a significant market share for sepsis diagnostics was held by the market in the North American region, comprising the US and Canada. The strong demand for and adoption of sepsis diagnostics in the US led to the growth of the Sepsis diagnostics market in this region.

A breakdown of the primary participants referred to for this report is provided below:

  • By Company Type: Tier 1- 25%, Tier 2- 30%, and Tier 3- 45%
  • By Designation: C-level- 26%, Directors- 30%, and Others- 44%
  • By Region: North America- 40%, Europe- 31%, Asia Pacific- 20%, Latin America- 6%, MEA- 3%

The prominent players in the sepsis diagnostics market are bioMerieux S.A. (France), Becton Dickinson and Company (US), Danaher Corporation (US), T2 Biosystems (US), QIAGEN N.V. (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Thermo Fisher Scientific (US), Bruker Corporation (US), Abbott Laboratories (US), among others.

Research Coverage

This report studies the sepsis diagnostics market based on technology, product, method, pathogen type, test type, end user, and region. It also covers the factors affecting market growth, analyzes the various opportunities and challenges in the market, and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five main regions (and the respective countries in these regions).

Reasons to Buy the Report

The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their market presence.

This report provides insights on the following pointers:

  • Analysis of key drivers (High incidence of sepsis, Rising incidence of hospital-acquired infections (HAIs), Growing funding for sepsis-related research), restraints (High cost of automated diagnostic devices), opportunities (Development of rapid diagnostic/POC techniques for early sepsis diagnosis, Evolution of novel biomarkers for sepsis diagnosis, Growth Opportunities in emerging economies), and challenges (Lack of awareness and limited protocols for sepsis diagnosis, Shortage of skilled healthcare professionals) influencing the growth of the sepsis diagnostics market
  • Market Penetration: Comprehensive information on the product portfolios offered by the top players in the sepsis diagnostics market
  • Service Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and service developments in the sepsis diagnostics market
  • Market Development: Comprehensive information on lucrative emerging regions
  • Market Diversification: Exhaustive information about new services, growing geographies, and recent developments in the sepsis diagnostics market
  • Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and services of the leading market players.
Show more
Product Code: MD 4575

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS AND EXCLUSIONS OF STUDY
  • 1.3 STUDY SCOPE
    • 1.3.1 MARKETS COVERED
    • 1.3.2 GEOGRAPHIES COVERED
    • 1.3.3 YEARS CONSIDERED
  • 1.4 CURRENCY
  • 1.5 MARKET STAKEHOLDERS
  • 1.6 SUMMARY OF CHANGES
    • 1.6.1 RECESSION IMPACT

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 1 RESEARCH DESIGN
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 Indicative list of secondary sources
    • 2.1.2 PRIMARY DATA
    • FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • 2.2 MARKET ESTIMATION METHODOLOGY
    • FIGURE 3 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
    • 2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION
    • FIGURE 4 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS (2023)
    • 2.2.2 APPROACH 1: PROCEDURE-BASED MARKET ESTIMATION
    • FIGURE 5 MARKET SIZE ESTIMATION: SEPSIS DIAGNOSTICS MARKET BASED ON PROCEDURE METHODOLOGY
    • 2.2.3 APPROACH 2: END USER-BASED MARKET ESTIMATION
    • FIGURE 6 MARKET SIZE ESTIMATION METHODOLOGY: SEPSIS DIAGNOSTICS MARKET
    • 2.2.4 PRIMARY RESEARCH VALIDATION
  • 2.3 DATA TRIANGULATION
    • FIGURE 7 DATA TRIANGULATION METHODOLOGY
  • 2.4 RESEARCH ASSUMPTIONS
  • 2.5 RESEARCH LIMITATIONS
  • 2.6 RISK ASSESSMENT
    • TABLE 1 SEPSIS DIAGNOSTICS MARKET: RISK ASSESSMENT ANALYSIS
    • 2.6.1 IMPACT OF RECESSION ON SEPSIS DIAGNOSTICS MARKET

3 EXECUTIVE SUMMARY

    • FIGURE 8 SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2024 VS. 2029 (USD MILLION)
    • FIGURE 9 SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024 VS. 2029 (USD MILLION)
    • FIGURE 10 SEPSIS DIAGNOSTICS MARKET SHARE, BY METHOD, 2024 VS. 2029
    • FIGURE 11 SEPSIS DIAGNOSTICS MARKET SHARE, BY TEST TYPE, 2024 VS. 2029
    • FIGURE 12 SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2024 VS. 2029 (USD MILLION)
    • FIGURE 13 SEPSIS DIAGNOSTICS MARKET SHARE, BY END USER, 2024 VS. 2029
    • FIGURE 14 GEOGRAPHICAL SNAPSHOT OF SEPSIS DIAGNOSTICS MARKET

4 PREMIUM INSIGHTS

  • 4.1 SEPSIS DIAGNOSTICS MARKET OVERVIEW
    • FIGURE 15 HIGH INCIDENCE OF SEPSIS TO DRIVE MARKET
  • 4.2 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT AND COUNTRY (2023)
    • FIGURE 16 BLOOD CULTURE MEDIA SEGMENT ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC MARKET IN 2023
  • 4.3 SEPSIS DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 17 CHINA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
  • 4.4 SEPSIS DIAGNOSTICS MARKET: REGIONAL MIX, 2022-2029 (USD MILLION)
    • FIGURE 18 NORTH AMERICA WILL CONTINUE TO DOMINATE SEPSIS DIAGNOSTICS MARKET DURING FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 19 SEPSIS DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 High incidence of sepsis
      • 5.2.1.2 Rising incidence of HAIs
      • 5.2.1.3 Growing funding for sepsis-related research
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 High cost of automated diagnostic devices
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Development of rapid diagnostic/POC techniques for early sepsis diagnosis
      • 5.2.3.2 Evolution of novel biomarkers for sepsis diagnosis
      • 5.2.3.3 Growth opportunities in emerging economies
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Lack of awareness and limited protocols for sepsis diagnosis
      • 5.2.4.2 Shortage of skilled healthcare professionals
  • 5.3 REGULATORY SCENARIO
    • 5.3.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 2 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AUTHORITIES, AND OTHER ORGANIZATIONS
    • TABLE 3 EUROPE: REGULATORY BODIES, GOVERNMENT AUTHORITIES, AND OTHER ORGANIZATIONS
    • TABLE 4 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AUTHORITIES, AND OTHER ORGANIZATIONS
    • TABLE 5 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AUTHORITIES, AND OTHER ORGANIZATIONS
    • TABLE 6 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AUTHORITIES, AND OTHER ORGANIZATIONS
    • 5.3.2 KEY REGULATORY GUIDELINES
      • 5.3.2.1 North America
        • 5.3.2.1.1 US
        • 5.3.2.1.2 Canada
      • 5.3.2.2 Europe
      • 5.3.2.3 Asia Pacific
        • 5.3.2.3.1 China
        • 5.3.2.3.2 Japan
        • 5.3.2.3.3 India
      • 5.3.2.4 Latin America
  • 5.4 REIMBURSEMENT SCENARIO
    • TABLE 7 MS DRG PAYMENT CALCULATED FOR NATIONAL PROVIDERS
  • 5.5 VALUE CHAIN ANALYSIS
    • 5.5.1 RESEARCH & DEVELOPMENT
    • 5.5.2 PROCUREMENT AND PRODUCT DEVELOPMENT
    • 5.5.3 MARKETING, SALES, AND DISTRIBUTION
    • FIGURE 20 VALUE CHAIN ANALYSIS
  • 5.6 SUPPLY CHAIN ANALYSIS
    • 5.6.1 PROMINENT COMPANIES
    • 5.6.2 SMALL & MEDIUM-SIZED ENTERPRISES
    • 5.6.3 END USERS
    • FIGURE 21 SUPPLY CHAIN ANALYSIS
  • 5.7 ECOSYSTEM COVERAGE
    • FIGURE 22 MARKET MAP
  • 5.8 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 8 SEPSIS DIAGNOSTICS MARKET: PORTER'S FIVE FORCES ANALYSIS
    • 5.8.1 INTENSITY OF COMPETITIVE RIVALRY
    • 5.8.2 BARGAINING POWER OF BUYERS
    • 5.8.3 BARGAINING POWER OF SUPPLIERS
    • 5.8.4 THREAT OF NEW ENTRANTS
    • 5.8.5 THREAT OF SUBSTITUTES
  • 5.9 TRADE DATA ANALYSIS
    • TABLE 9 IMPORT DATA FOR HERNIA MESH (HS CODE 902190), BY COUNTRY, 2018-2022 (USD)
    • TABLE 10 EXPORT DATA FOR HERNIA MESHES (HS CODE 902190), BY COUNTRY, 2018-2022 (USD)
  • 5.10 PATENT ANALYSIS
    • FIGURE 23 PATENT ANALYSIS
  • 5.11 PRICING ANALYSIS
    • 5.11.1 AVERAGE SELLING PRICE TREND, BY REGION
    • TABLE 11 SEPSIS DIAGNOSTICS PRICING ANALYSIS, BY REGION, 2023 (USD)
    • 5.11.2 AVERAGE SELLING PRICE TREND, BY KEY PLAYER
    • TABLE 12 HERNIA REPAIR PRICING ANALYSIS, BY KEY PLAYER, 2023 (USD)
  • 5.12 TECHNOLOGY ANALYSIS
    • 5.12.1 KEY TECHNOLOGIES
      • 5.12.1.1 Biomarkers
      • 5.12.1.2 Microfluidics
    • 5.12.2 COMPLIMENTARY TECHNOLOGIES
      • 5.12.2.1 Genomics and Transcriptomics
      • 5.12.2.2 Machine Learning and Artificial Intelligence (AI)
    • 5.12.3 ADJACENT TECHNOLOGIES
      • 5.12.3.1 Nanotechnology Sensors
      • 5.12.3.2 Medical Imaging
      • 5.12.3.3 Digital Health Solutions
  • 5.13 KEY CONFERENCES AND EVENTS IN 2023-2024
    • TABLE 13 SEPSIS DIAGNOSTICS: LIST OF MAJOR CONFERENCES & EVENTS
  • 5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS
    • FIGURE 24 EMERGING TRENDS AND OPPORTUNITIES AFFECTING FUTURE REVENUE MIX
  • 5.15 SEPSIS DIAGNOSTICS MARKET: RECESSION IMPACT
  • 5.16 KEY STAKEHOLDERS AND BUYING CRITERIA
    • 5.16.1 KEY STAKEHOLDERS
    • FIGURE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS
    • TABLE 14 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR PRODUCT SEGMENTS (%)
    • 5.16.2 KEY BUYING CRITERIA
    • FIGURE 26 KEY BUYING CRITERIA FOR SEPSIS DIAGNOSTIC PRODUCTS
    • TABLE 15 KEY BUYING CRITERIA FOR SEPSIS DIAGNOSTIC PRODUCTS
  • 5.17 UNMET NEEDS AND KEY PAIN POINTS
    • TABLE 16 SEPSIS DIAGNOSTICS MARKET: UNMET CUSTOMER NEEDS AND KEY PAIN POINTS
  • 5.18 INVESTMENT SCENARIO
    • FIGURE 27 NUMBER OF INVESTOR DEALS IN SEPSIS DIAGNOSTICS MARKET, BY KEY PLAYER, 2018-2022
    • FIGURE 28 VALUE OF INVESTOR DEALS IN SEPSIS DIAGNOSTICS MARKET, BY KEY PLAYER, 2018-2022 (USD MILLION)

6 SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY

  • 6.1 INTRODUCTION
    • TABLE 17 SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • 6.2 BLOOD CULTURE (MICROBIOLOGY TESTING)
    • 6.2.1 MOST COMMONLY ADOPTED TECHNOLOGY FOR SEPSIS DIAGNOSTICS
    • TABLE 18 BLOOD CULTURE MARKET, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 19 BLOOD CULTURE MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 20 BLOOD CULTURE MARKET, BY METHOD, 2022-2029 (USD MILLION)
    • TABLE 21 BLOOD CULTURE MARKET, BY PATHOGEN TYPE, 2022-2029 (USD MILLION)
    • TABLE 22 BLOOD CULTURE MARKET FOR BACTERIAL SEPSIS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 23 BLOOD CULTURE MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
    • TABLE 24 BLOOD CULTURE MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 6.3 IMMUNOASSAYS
    • 6.3.1 RISING PRODUCT DEVELOPMENT BY MAJOR PLAYERS TO SUPPORT MARKET GROWTH
    • TABLE 25 IMMUNOASSAYS MARKET, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 26 IMMUNOASSAYS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 27 IMMUNOASSAYS MARKET, BY METHOD, 2022-2029 (USD MILLION)
    • TABLE 28 IMMUNOASSAYS MARKET, BY PATHOGEN TYPE, 2022-2029 (USD MILLION)
    • TABLE 29 IMMUNOASSAYS MARKET FOR BACTERIAL SEPSIS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 30 IMMUNOASSAYS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
    • TABLE 31 IMMUNOASSAYS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 6.4 MOLECULAR DIAGNOSTICS
    • TABLE 32 MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 33 MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 34 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 35 MOLECULAR DIAGNOSTICS MARKET, BY METHOD, 2022-2029 (USD MILLION)
    • TABLE 36 MOLECULAR DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2022-2029 (USD MILLION)
    • TABLE 37 MOLECULAR DIAGNOSTICS MARKET FOR BACTERIAL SEPSIS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 38 MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
    • TABLE 39 MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 6.4.1 POLYMERASE CHAIN REACTION
      • 6.4.1.1 Quick turnaround time and technological advancements to propel market
    • TABLE 40 POLYMERASE CHAIN REACTION MARKET, BY REGION, 2022-2029 (USD MILLION)
    • 6.4.2 MICROARRAYS
      • 6.4.2.1 Simultaneous analysis capabilities & accuracy to boost adoption
    • TABLE 41 MICROARRAYS MARKET, BY REGION, 2022-2029 (USD MILLION)
    • 6.4.3 PEPTIDE NUCLEIC ACID-FLUORESCENT IN SITU HYBRIDIZATION
      • 6.4.3.1 Enables rapid diagnosis of bloodstream infections
    • TABLE 42 PEPTIDE NUCLEIC ACID-FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY REGION, 2022-2029 (USD MILLION)
    • 6.4.4 DNA SEQUENCING
      • 6.4.4.1 Shortens time for sepsis diagnosis
    • TABLE 43 DNA SEQUENCING MARKET, BY REGION, 2022-2029 (USD MILLION)
  • 6.5 FLOW CYTOMETRY
    • 6.5.1 LACK OF STANDARDIZED PROTOCOLS-KEY FACTOR RESTRAINING MARKET GROWTH
    • TABLE 44 FLOW CYTOMETRY MARKET, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 45 FLOW CYTOMETRY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 46 FLOW CYTOMETRY MARKET, BY METHOD, 2022-2029 (USD MILLION)
    • TABLE 47 FLOW CYTOMETRY MARKET, BY PATHOGEN TYPE, 2022-2029 (USD MILLION)
    • TABLE 48 FLOW CYTOMETRY MARKET FOR BACTERIAL SEPSIS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 49 FLOW CYTOMETRY MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
    • TABLE 50 FLOW CYTOMETRY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 6.6 MICROFLUIDICS
    • 6.6.1 RISING ADOPTION OF ADVANCED AND RAPID TESTING TO DRIVE GROWTH
    • TABLE 51 MICROFLUIDICS MARKET, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 52 MICROFLUIDICS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 53 MICROFLUIDICS MARKET, BY METHOD, 2022-2029 (USD MILLION)
    • TABLE 54 MICROFLUIDICS MARKET, BY PATHOGEN TYPE, 2022-2029 (USD MILLION)
    • TABLE 55 MICROFLUIDICS MARKET FOR BACTERIAL SEPSIS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 56 MICROFLUIDICS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
    • TABLE 57 MICROFLUIDICS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 6.7 BIOMARKERS
    • 6.7.1 RESEARCH & DEVELOPMENT FOR DISCOVERY OF NOVEL BIOMARKERS TO DRIVE GROWTH
    • TABLE 58 BIOMARKERS MARKET, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 59 BIOMARKERS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 60 BIOMARKERS MARKET, BY METHOD, 2022-2029 (USD MILLION)
    • TABLE 61 BIOMARKERS MARKET, BY PATHOGEN TYPE, 2022-2029 (USD MILLION)
    • TABLE 62 BIOMARKERS MARKET FOR BACTERIAL SEPSIS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 63 BIOMARKERS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
    • TABLE 64 BIOMARKERS MARKET, BY END USER, 2022-2029 (USD MILLION)

7 SEPSIS DIAGNOSTICS MARKET, BY PRODUCT

  • 7.1 INTRODUCTION
    • TABLE 65 SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • 7.2 BLOOD CULTURE MEDIA
    • 7.2.1 RISE IN BLOODSTREAM INFECTIONS TO DRIVE GROWTH
    • TABLE 66 SEPSIS DIAGNOSTIC BLOOD CULTURE MEDIA MARKET, BY REGION, 2022-2029 (USD MILLION)
  • 7.3 ASSAYS & REAGENT KITS
    • 7.3.1 ASSAYS BETTER ENABLE ANALYSIS OF PATIENT SAMPLES FOR DISEASE DIAGNOSIS
    • TABLE 67 SEPSIS DIAGNOSTIC ASSAYS & REAGENT KITS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • 7.4 INSTRUMENTS
    • 7.4.1 INCREASING INCLINATION TOWARD RAPID DIAGNOSTIC SYSTEMS TO DRIVE MARKET
    • TABLE 68 SEPSIS DIAGNOSTIC INSTRUMENTS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • 7.5 SOFTWARE
    • 7.5.1 INCREASING USE OF AUTOMATED INSTRUMENTS TO DRIVE DEMAND FOR SOFTWARE
    • TABLE 69 SEPSIS DIAGNOSTIC SOFTWARE MARKET, BY REGION, 2022-2029 (USD MILLION)

8 SEPSIS DIAGNOSTICS MARKET, BY METHOD

  • 8.1 INTRODUCTION
    • TABLE 70 SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2022-2029 (USD MILLION)
  • 8.2 CONVENTIONAL DIAGNOSTICS
    • 8.2.1 EASE OF USE AND LOW COST TO PROPEL MARKET GROWTH
    • TABLE 71 CONVENTIONAL SEPSIS DIAGNOSTICS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • 8.3 AUTOMATED DIAGNOSTICS
    • 8.3.1 ACCURACY AND QUICK TURNAROUND TIME TO DRIVE ADOPTION
    • TABLE 72 AUTOMATED SEPSIS DIAGNOSTICS MARKET, BY REGION, 2022-2029 (USD MILLION)

9 SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE

  • 9.1 INTRODUCTION
    • TABLE 73 SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2022-2029 (USD MILLION)
  • 9.2 BACTERIAL SEPSIS
    • TABLE 74 BACTERIAL SEPSIS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 75 BACTERIAL SEPSIS MARKET, BY REGION, 2022-2029 (USD MILLION)
    • 9.2.1 GRAM-NEGATIVE BACTERIAL SEPSIS
      • 9.2.1.1 Increasing demand for sepsis diagnostic tests to drive market
    • TABLE 76 GRAM-NEGATIVE BACTERIAL CAUSES IN ADULTS
    • TABLE 77 GRAM-NEGATIVE BACTERIAL SEPSIS MARKET, BY REGION, 2022-2029 (USD MILLION)
    • 9.2.2 GRAM-POSITIVE BACTERIAL SEPSIS
      • 9.2.2.1 Increasing incidence of gram-positive nosocomial infections to propel market
    • TABLE 78 GRAM-POSITIVE BACTERIAL CAUSES IN ADULTS
    • TABLE 79 GRAM-POSITIVE BACTERIAL SEPSIS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • 9.3 FUNGAL SEPSIS
    • 9.3.1 RISING INCIDENCE OF FUNGAL INFECTIONS TO PROPEL MARKET
    • TABLE 80 FUNGAL SEPSIS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • 9.4 OTHER PATHOGEN TYPES
    • TABLE 81 OTHER PATHOGEN TYPES MARKET, BY REGION, 2022-2029 (USD MILLION)

10 SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE

  • 10.1 INTRODUCTION
    • TABLE 82 SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
  • 10.2 LABORATORY TESTS
    • 10.2.1 MOST COMMON AND PREFERRED MODE OF TESTING
    • TABLE 83 LABORATORY SEPSIS DIAGNOSTIC TESTS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • 10.3 POINT-OF-CARE TESTS
    • 10.3.1 INCREASING DEVELOPMENT OF NOVEL POC DIAGNOSTICS TO SUPPORT MARKET GROWTH
    • TABLE 84 POINT-OF-CARE SEPSIS DIAGNOSTIC TESTS MARKET, BY REGION, 2022-2029 (USD MILLION)

11 SEPSIS DIAGNOSTICS MARKET, BY END USER

  • 11.1 INTRODUCTION
    • TABLE 85 SEPSIS DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 11.2 HOSPITALS AND SPECIALTY CLINICS
    • 11.2.1 INCREASING ADOPTION OF SEPSIS DIAGNOSTIC PRODUCTS BY IN-HOUSE HOSPITAL LABS TO DRIVE MARKET
    • TABLE 86 SEPSIS DIAGNOSTICS MARKET FOR HOSPITALS AND SPECIALTY CLINICS, BY REGION, 2022-2029 (USD MILLION)
  • 11.3 PATHOLOGY AND REFERENCE LABORATORIES
    • 11.3.1 INDEPENDENT LABORATORIES OFFER AFFORDABLE AND EFFICIENT DIAGNOSTIC SERVICES
    • TABLE 87 SEPSIS DIAGNOSTICS MARKET FOR PATHOLOGY AND REFERENCE LABORATORIES, BY REGION, 2022-2029 (USD MILLION)
  • 11.4 RESEARCH LABORATORIES, ACADEMIC INSTITUTES, AND CROS
    • 11.4.1 GOVERNMENT SUPPORT AND RISING AWARENESS FOR EARLY SEPSIS DETECTION TO DRIVE GROWTH
    • TABLE 88 SEPSIS DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES, ACADEMIC INSTITUTES, AND CROS, BY REGION, 2022-2029 (USD MILLION)

12 SEPSIS DIAGNOSTICS MARKET, BY REGION

  • 12.1 INTRODUCTION
    • TABLE 89 SEPSIS DIAGNOSTICS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • 12.2 NORTH AMERICA
    • FIGURE 29 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET SNAPSHOT
    • TABLE 90 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 91 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 92 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 93 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 94 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2022-2029 (USD MILLION)
    • TABLE 95 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2022-2029 (USD MILLION)
    • TABLE 96 NORTH AMERICA: BACTERIAL SEPSIS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 97 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
    • TABLE 98 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 12.3 RECESSION IMPACT ON NORTH AMERICAN SEPSIS DIAGNOSTICS MARKET
    • 12.3.1 US
      • 12.3.1.1 Rising incidence of HAIs to drive demand
    • TABLE 99 US: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 100 US: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • 12.3.2 CANADA
      • 12.3.2.1 Growing availability of sepsis diagnostic products to support market growth
    • TABLE 101 CANADA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 102 CANADA: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • 12.4 EUROPE
    • TABLE 103 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 104 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 105 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 106 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 107 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2022-2029 (USD MILLION)
    • TABLE 108 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2022-2029 (USD MILLION)
    • TABLE 109 EUROPE: BACTERIAL SEPSIS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 110 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
    • TABLE 111 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 12.4.1 RECESSION IMPACT ON EUROPEAN SEPSIS DIAGNOSTICS MARKET
    • 12.4.2 GERMANY
      • 12.4.2.1 Adoption of technologically advanced diagnostic products to drive market
    • TABLE 112 GERMANY: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 113 GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • 12.4.3 UK
      • 12.4.3.1 Stringent government regulations to drive market growth
    • TABLE 114 UK: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 115 UK: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • 12.4.4 FRANCE
      • 12.4.4.1 High incidence of sepsis to propel growth
    • TABLE 116 FRANCE: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 117 FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • 12.4.5 ITALY
      • 12.4.5.1 Supportive government initiatives for raising awareness on sepsis to drive market
    • TABLE 118 ITALY: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 119 ITALY: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • 12.4.6 SPAIN
      • 12.4.6.1 Rising awareness for early diagnosis of propel market
    • TABLE 120 SPAIN: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 121 SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • 12.4.7 REST OF EUROPE
    • TABLE 122 REST OF EUROPE: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 123 REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • 12.5 ASIA PACIFIC
    • FIGURE 30 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET SNAPSHOT
    • TABLE 124 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 125 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 126 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 127 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 128 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2022-2029 (USD MILLION)
    • TABLE 129 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2022-2029 (USD MILLION)
    • TABLE 130 ASIA PACIFIC: BACTERIAL SEPSIS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 131 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
    • TABLE 132 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 12.5.1 RECESSION IMPACT ON ASIA PACIFIC SEPSIS DIAGNOSTICS MARKET
    • 12.5.2 JAPAN
      • 12.5.2.1 Rising incidence of pneumonia and infectious diseases to support market growth
    • TABLE 133 JAPAN: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 134 JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • 12.5.3 CHINA
      • 12.5.3.1 Healthcare infrastructure improvements to support market growth
    • TABLE 135 CHINA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 136 CHINA: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • 12.5.4 INDIA
      • 12.5.4.1 Increasing patient population and rising number of surgical procedures to drive market
    • TABLE 137 INDIA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 138 INDIA: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • 12.5.5 AUSTRALIA
      • 12.5.5.1 Rapid growth in sepsis treatment procedures to propel market
    • TABLE 139 AUSTRALIA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 140 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • 12.5.6 SOUTH KOREA
      • 12.5.6.1 Rising healthcare spending to support market growth
    • TABLE 141 SOUTH KOREA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 142 SOUTH KOREA: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • 12.5.7 REST OF ASIA PACIFIC
    • TABLE 143 REST OF ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 144 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • 12.6 LATIN AMERICA
    • TABLE 145 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 146 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 147 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 148 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 149 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2022-2029 (USD MILLION)
    • TABLE 150 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2022-2029 (USD MILLION)
    • TABLE 151 LATIN AMERICA: BACTERIAL SEPSIS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 152 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
    • TABLE 153 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 12.6.1 RECESSION IMPACT ON LATIN AMERICAN SEPSIS DIAGNOSTICS MARKET
    • 12.6.2 BRAZIL
      • 12.6.2.1 Investments by leading sepsis diagnostic manufacturers to support market growth
    • TABLE 154 BRAZIL: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 155 BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • 12.6.3 MEXICO
      • 12.6.3.1 Rising medical tourism to drive market
    • TABLE 156 MEXICO: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 157 MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • 12.6.4 REST OF LATIN AMERICA
    • TABLE 158 REST OF LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 159 REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • 12.7 MIDDLE EAST & AFRICA
    • 12.7.1 HIGH CONSUMPTION OF IMMUNE SYSTEM-SUPPRESSING MEDICATIONS TO PROPEL MARKET
    • TABLE 160 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 161 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 162 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 163 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 164 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2022-2029 (USD MILLION)
    • TABLE 165 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2022-2029 (USD MILLION)
    • TABLE 166 MIDDLE EAST & AFRICA: BACTERIAL SEPSIS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 167 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
    • TABLE 168 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 12.7.2 RECESSION IMPACT ON MIDDLE EAST & AFRICAN SEPSIS DIAGNOSTICS MARKET
    • 12.7.3 GCC COUNTRIES
      • 12.7.3.1 Developments in healthcare infrastructure to drive market
    • TABLE 169 GCC COUNTRIES: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 170 GCC COUNTRIES: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • 12.7.4 REST OF MIDDLE EAST & AFRICA
    • TABLE 171 REST OF MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 172 REST OF MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD MILLION)

13 COMPETITIVE LANDSCAPE

  • 13.1 INTRODUCTION
  • 13.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS
    • FIGURE 31 SEPSIS DIAGNOSTICS MARKET: STRATEGIES ADOPTED
  • 13.3 REVENUE SHARE ANALYSIS
    • FIGURE 32 REVENUE SHARE ANALYSIS OF KEY PLAYERS, 2020-2022 (USD MILLION)
  • 13.4 MARKET SHARE ANALYSIS
    • 13.4.1 SEPSIS DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
    • FIGURE 33 SEPSIS DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
    • TABLE 173 SEPSIS DIAGNOSTICS MARKET: DEGREE OF COMPETITION
    • 13.4.2 BLOOD CULTURE MARKET SHARE, BY KEY PLAYER, 2023
    • FIGURE 34 BLOOD CULTURE MARKET SHARE, BY KEY PLAYER, 2023
    • 13.4.3 IMMUNOASSAY MARKET SHARE, BY KEY PLAYER, 2023
    • FIGURE 35 IMMUNOASSAYS MARKET SHARE, BY KEY PLAYER, 2023
    • 13.4.4 MOLECULAR DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
    • FIGURE 36 MOLECULAR DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
    • 13.4.5 BIOMARKER MARKET SHARE, BY KEY PLAYER, 2023
    • FIGURE 37 BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2023
    • FIGURE 38 SEPSIS DIAGNOSTICS MARKET RANKING (2023)
  • 13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS
    • 13.5.1 STARS
    • 13.5.2 EMERGING LEADERS
    • 13.5.3 PERVASIVE PLAYERS
    • 13.5.4 PARTICIPANTS
    • FIGURE 39 SEPSIS DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
    • 13.5.5 COMPETITIVE FOOTPRINT
      • 13.5.5.1 Overall company footprint
    • FIGURE 40 SEPSIS DIAGNOSTICS MARKET: OVERALL COMPANY FOOTPRINT
      • 13.5.5.2 Regional footprint
    • TABLE 174 SEPSIS DIAGNOSTICS MARKET: REGIONAL FOOTPRINT
      • 13.5.5.3 Technology footprint
    • TABLE 175 SEPSIS DIAGNOSTICS MARKET: TECHNOLOGY FOOTPRINT
      • 13.5.5.4 Product footprint
    • TABLE 176 SEPSIS DIAGNOSTICS MARKET: PRODUCT FOOTPRINT
      • 13.5.5.5 Pathogen type footprint
    • TABLE 177 SEPSIS DIAGNOSTICS MARKET: PATHOGEN TYPE FOOTPRINT
  • 13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES
    • 13.6.1 PROGRESSIVE COMPANIES
    • 13.6.2 RESPONSIVE COMPANIES
    • 13.6.3 DYNAMIC COMPANIES
    • 13.6.4 STARTING BLOCKS
    • FIGURE 41 SEPSIS DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
    • 13.6.5 COMPETITIVE BENCHMARKING
    • TABLE 178 SEPSIS DIAGNOSTICS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
    • TABLE 179 SEPSIS DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES
  • 13.7 VALUATION AND FINANCIAL METRICS OF SEPSIS DIAGNOSTIC VENDORS
    • FIGURE 42 EV/EBITDA OF KEY VENDORS
    • FIGURE 43 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • 13.8 PRODUCT/BRAND COMPARATIVE ANALYSIS
    • FIGURE 44 BRAND/PRODUCT COMPARATIVE ANALYSIS, BY MODEL (2023)
    • 13.8.1 BIOMERIEUX
    • 13.8.2 BECTON, DICKINSON AND COMPANY
    • 13.8.3 F. HOFFMANN-LA ROCHE LTD.
    • 13.8.4 DANAHER CORPORATION
    • 13.8.5 QIAGEN N.V.
  • 13.9 COMPETITIVE SCENARIO
    • 13.9.1 PRODUCT LAUNCHES & APPROVALS
    • TABLE 180 SEPSIS DIAGNOSTICS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2019-MARCH 2024
    • 13.9.2 DEALS
    • TABLE 181 SEPSIS DIAGNOSTICS MARKET: DEALS, JANUARY 2019-MARCH 2024
    • 13.9.3 EXPANSIONS
    • TABLE 182 SEPSIS DIAGNOSTICS MARKET: EXPANSIONS, JANUARY 2019-MARCH 2024

14 COMPANY PROFILES

(Business overview, Products offered, Recent Developments, MNM view)**

  • 14.1 KEY PLAYERS
    • 14.1.1 BIOMERIEUX
    • TABLE 183 BIOMERIEUX: COMPANY OVERVIEW
    • FIGURE 45 BIOMERIEUX: COMPANY SNAPSHOT (2022)
    • TABLE 184 BIOMERIEUX: PRODUCTS OFFERED
    • TABLE 185 BIOMERIEUX: PRODUCT LAUNCHES & APPROVALS
    • TABLE 186 BIOMERIEUX: DEALS
    • TABLE 187 BIOMERIEUX: OTHER DEVELOPMENTS
    • 14.1.2 BECTON, DICKINSON AND COMPANY
    • TABLE 188 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW
    • FIGURE 46 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2023)
    • TABLE 189 BECTON, DICKINSON AND COMPANY: PRODUCTS OFFERED
    • TABLE 190 BECTON, DICKINSON AND COMPANY: PRODUCT LAUNCHES & APPROVALS
    • TABLE 191 BECTON, DICKINSON AND COMPANY: EXPANSIONS
    • 14.1.3 DANAHER CORPORATION
    • TABLE 192 DANAHER CORPORATION: COMPANY OVERVIEW
    • FIGURE 47 DANAHER CORPORATION: COMPANY SNAPSHOT (2022)
    • TABLE 193 DANAHER CORPORATION: PRODUCTS OFFERED
    • TABLE 194 DANAHER CORPORATION: PRODUCT LAUNCHES & APPROVALS
    • TABLE 195 DANAHER CORPORATION: DEALS
    • 14.1.4 T2 BIOSYSTEMS, INC.
    • TABLE 196 T2 BIOSYSTEMS INC.: COMPANY OVERVIEW
    • FIGURE 48 T2 BIOSYSTEMS INC.: COMPANY SNAPSHOT (2022)
    • TABLE 197 T2 BIOSYSTEMS, INC.: PRODUCTS OFFERED
    • TABLE 198 T2 BIOSYSTEMS, INC.: PRODUCT LAUNCHES & APPROVALS
    • TABLE 199 T2 BIOSYSTEMS, INC.: DEALS
    • TABLE 200 T2 BIOSYSTEMS, INC.: EXPANSIONS
    • 14.1.5 DIASORIN S.P.A.
    • TABLE 201 DIASORIN S.P.A.: COMPANY OVERVIEW
    • FIGURE 49 DIASORIN S.P.A.: COMPANY SNAPSHOT (2022)
    • TABLE 202 DIASORIN S.P.A.: PRODUCTS OFFERED
    • TABLE 203 DIASORIN S.P.A.: PRODUCT LAUNCHES & APPROVALS
    • TABLE 204 DIASORIN S.P.A.: DEALS
    • 14.1.6 F. HOFFMANN-LA ROCHE LTD.
    • TABLE 205 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
    • FIGURE 50 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022)
    • TABLE 206 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED
    • TABLE 207 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES & APPROVALS
    • TABLE 208 F. HOFFMANN-LA ROCHE LTD.: DEALS
    • 14.1.7 THERMO FISHER SCIENTIFIC INC.
    • TABLE 209 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
    • FIGURE 51 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023)
    • TABLE 210 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED
    • TABLE 211 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES & APPROVALS
    • TABLE 212 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS
    • TABLE 213 THERMO FISHER SCIENTIFIC INC.: OTHER DEVELOPMENTS
    • 14.1.8 BRUKER CORPORATION
    • TABLE 214 BRUKER CORPORATION: COMPANY OVERVIEW
    • FIGURE 52 BRUKER CORPORATION: COMPANY SNAPSHOT (2022)
    • TABLE 215 BRUKER CORPORATION: PRODUCTS OFFERED
    • TABLE 216 BRUKER CORPORATION: PRODUCT LAUNCHES & APPROVALS
    • TABLE 217 BRUKER CORPORATION: DEALS
    • 14.1.9 QUIDELORTHO CORPORATION
    • TABLE 218 QUIDELORTHO CORPORATION: COMPANY OVERVIEW
    • FIGURE 53 QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2022)
    • TABLE 219 QUIDELORTHO CORPORATION: PRODUCTS OFFERED
    • 14.1.10 SYSMEX CORPORATION
    • TABLE 220 SYSMEX CORPORATION: COMPANY OVERVIEW
    • FIGURE 54 SYSMEX CORPORATION: COMPANY SNAPSHOT (2023)
    • TABLE 221 SYSMEX CORPORATION: PRODUCTS OFFERED
    • TABLE 222 SYSMEX CORPORATION: PRODUCT LAUNCHES & APPROVALS
    • TABLE 223 SYSMEX CORPORATION: OTHER DEVELOPMENTS
    • 14.1.11 ABBOTT LABORATORIES
    • TABLE 224 ABBOTT LABORATORIES: COMPANY OVERVIEW
    • FIGURE 55 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2023)
    • TABLE 225 ABBOTT LABORATORIES: PRODUCTS OFFERED
    • 14.1.12 SIEMENS HEALTHINEERS
    • TABLE 226 SIEMENS HEALTHINEERS: COMPANY OVERVIEW
    • FIGURE 56 SIEMENS HEALTHINEERS: COMPANY SNAPSHOT (2023)
    • TABLE 227 SIEMENS HEALTHINEERS: PRODUCTS OFFERED
    • TABLE 228 SIEMENS HEALTHINEERS: PRODUCT APPROVALS
    • TABLE 229 SIEMENS HEALTHINEERS: DEALS
    • TABLE 230 SIEMENS HEALTHINEERS: EXPANSIONS
    • 14.1.13 QIAGEN N.V.
    • TABLE 231 QIAGEN N.V.: COMPANY OVERVIEW
    • FIGURE 57 QIAGEN N.V.: COMPANY SNAPSHOT (2022)
    • TABLE 232 QIAGEN N.V.: PRODUCTS OFFERED
    • TABLE 233 QIAGEN N.V.: DEALS
    • TABLE 234 QIAGEN N.V.: EXPANSIONS
    • 14.1.14 SEEGENE, INC.
    • TABLE 235 SEEGENE, INC.: COMPANY OVERVIEW
    • TABLE 236 SEEGENE, INC.: PRODUCTS OFFERED
    • 14.1.15 PHC HOLDINGS CORPORATION
    • TABLE 237 PHC HOLDINGS CORPORATION: COMPANY OVERVIEW
    • TABLE 238 PHC HOLDINGS CORPORATION: PRODUCTS OFFERED
    • TABLE 239 PHC HOLDINGS CORPORATION: DEALS
  • 14.2 OTHER PLAYERS
    • 14.2.1 MCKESSON CORPORATION
    • TABLE 240 MCKESSON CORPORATION: COMPANY OVERVIEW
    • 14.2.2 EKF DIAGNOSTICS HOLDINGS PLC
    • TABLE 241 EKF DIAGNOSTICS HOLDINGS PLC: COMPANY OVERVIEW
    • 14.2.3 RESPONSE BIOMEDICAL CORP.
    • TABLE 242 RESPONSE BIOMEDICAL CORP.: COMPANY OVERVIEW
    • 14.2.4 ALIFAX S.R.L.
    • TABLE 243 ALIFAX S.R.L.: COMPANY OVERVIEW
    • 14.2.5 BODITECH MED INC.
    • TABLE 244 BODITECH MED INC.: COMPANY OVERVIEW
    • 14.2.6 ADVANDX
    • TABLE 245 ADVANDX: COMPANY OVERVIEW
    • 14.2.7 IMMUNEXPRESS INC.
    • TABLE 246 IMMUNEXPRESS INC.: COMPANY OVERVIEW
    • 14.2.8 AXIS-SHIELD DIAGNOSTICS
    • TABLE 247 AXIS-SHIELD DIAGNOSTICS: COMPANY OVERVIEW
    • 14.2.9 FUJIREBIO
    • TABLE 248 FUJIREBIO: COMPANY OVERVIEW
    • 14.2.10 SEKISUI DIAGNOSTICS
    • TABLE 249 SEKISUI DIAGNOSTICS: COMPANY OVERVIEW
    • 14.2.11 CURETIS GMBH
    • TABLE 250 CURETIS GMBH: COMPANY OVERVIEW
    • 14.2.12 NANOMIX INC.
    • TABLE 251 NANOMIX INC.: COMPANY OVERVIEW
    • 14.2.13 QVELLA CORPORATION
    • TABLE 252 QVELLA CORPORATION: COMPANY OVERVIEW
    • 14.2.14 MOLZYM GMBH & CO. KG
    • TABLE 253 MOLZYM GMBH & CO. KG: COMPANY OVERVIEW
    • 14.2.15 CYTOVALE, INC.
    • TABLE 254 CYTOVALE, INC.: COMPANY OVERVIEW
  • *Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.

15 APPENDIX

  • 15.1 DISCUSSION GUIDE
  • 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 15.3 CUSTOMIZATION OPTIONS
  • 15.4 RELATED REPORTS
  • 15.5 AUTHOR DETAILS
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!